Your browser is no longer supported. Please, upgrade your browser.
NVO Novo Nordisk A/S daily Stock Chart
Novo Nordisk A/S
Index- P/E27.42 EPS (ttm)2.02 Insider Own26.40% Shs Outstand2.03B Perf Week2.82%
Market Cap112.33B Forward P/E22.42 EPS next Y2.47 Insider Trans0.00% Shs Float1.36B Perf Month-1.07%
Income5.18B PEG2.34 EPS next Q0.58 Inst Own10.20% Short Float0.17% Perf Quarter9.77%
Sales16.55B P/S6.79 EPS this Y34.30% Inst Trans-2.32% Short Ratio1.76 Perf Half Y4.02%
Book/sh2.21 P/B25.09 EPS next Y8.61% ROA40.40% Target Price60.10 Perf Year-0.10%
Cash/sh0.66 P/C84.31 EPS next 5Y11.70% ROE82.70% 52W Range45.37 - 59.29 Perf YTD-2.86%
Dividend0.96 P/FCF39.95 EPS past 5Y22.40% ROI85.00% 52W High-6.49% Beta0.78
Dividend %1.73% Quick Ratio0.80 Sales past 5Y12.20% Gross Margin84.90% 52W Low22.20% ATR0.86
Employees41571 Current Ratio1.10 Sales Q/Q8.00% Oper. Margin43.60% RSI (14)54.69 Volatility1.11% 1.26%
OptionableYes Debt/Eq0.01 EPS Q/Q-2.20% Profit Margin31.30% Rel Volume1.05 Prev Close56.05
ShortableYes LT Debt/Eq0.00 EarningsApr 29 BMO Payout47.50% Avg Volume1.30M Price55.44
Recom1.00 SMA201.56% SMA500.59% SMA2002.37% Volume1,361,415 Change-1.09%
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Feb-24-10Upgrade Jefferies & Co Hold → Buy
Jan-15-10Downgrade Jefferies & Co Buy → Hold
Sep-11-09Initiated Jefferies & Co Buy
Aug-07-09Downgrade UBS Buy → Neutral
Aug-07-09Downgrade JP Morgan Overweight → Neutral
May-12-09Initiated Piper Jaffray Buy
Apr-24-09Upgrade Citigroup Hold → Buy
Mar-26-09Upgrade UBS Neutral → Buy
Jan-14-09Downgrade Citigroup Hold → Sell
Oct-06-08Upgrade Deutsche Securities Hold → Buy
Aug-29-08Downgrade Bernstein Mkt Perform → Underperform
Aug-21-08Initiated UBS Neutral
Jun-09-08Upgrade HSBC Securities Underweight → Neutral
Feb-26-08Downgrade Bear Stearns Outperform → Peer Perform
May-25-16 04:32PM  U.S. panel backs approval of Sanofi combination diabetes drug Reuters
03:50PM  Novo Nordisk IDegLira Recommended by FDA Advisory Committee
03:19AM  European shares hit new 4-week high, Novo Nordisk leads
May-24-16 04:27PM  U.S. FDA panel recommends approval of Novo Nordisk diabetes drug Reuters
May-23-16 07:44PM  Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles at Fortune
01:05PM  FDA staff question usefulness of Sanofi diabetes drugs Reuters
09:18AM  FDA Staff Questions Usefulness of Sanofis Diabetes Drug Combo at Bloomberg
May-20-16 10:07AM  FDA staff question utility, trials of Novo Nordisk diabetes drug Reuters
08:50AM  FDA staff question utility of Novo Nordisk combo diabetes drug Reuters
May-18-16 10:35AM  Renaissance Technologies Bullish on PepsiCo (PEP) and Gold Heading Into Q2 at Insider Monkey
May-16-16 08:00AM  Emisphere Reports First Quarter 2016 Financial Results GlobeNewswire
May-13-16 06:02AM  We're Focused on What We're Good At, Says Nordisk CEO
06:02AM  We're Focused on What We're Good At, Says Nordisk CEO at Bloomberg
May-11-16 07:51PM  ETFs with exposure to Novo Nordisk A/S : May 11, 2016
May-10-16 10:14AM  Novo Nordisk A/S :NVO-US: Earnings Analysis: Q1, 2016 By the Numbers
May-09-16 05:06PM  Will Novos Modern Insulin Portfolio Fall Soon?
May-06-16 12:06PM  Novos Geographical Sales Split in 1Q16 Market Realist
May-05-16 07:11PM  Novo Nordisk A/S Injecting Future Sales at Motley Fool
May-03-16 03:30PM  Saxenda® demonstrated similar efficacy and safety profile across obesity severity stages CNW Group
May-02-16 08:00PM  Vanguard Launches 2 Dividend-Oriented International ETFs (VIGI, VYMI) at Investopedia
03:38PM  Novo Impressed Wall Street with Its 1Q16 Earnings Market Realist
03:38PM  How Has Novos Share Price Performed since Its Last Earnings? Market Realist
12:02PM  Novo Nordisk (NVO) Beats on Q1 Earnings, Retains Outlook Zacks
Apr-26-16 02:53PM  Stocks Are Mixed as Oil Jumps 3% at TheStreet
09:51AM  Lilly (LLY) Raises View despite Q1 Earnings & Revenue Miss Zacks
Apr-21-16 10:26AM  5 Large-Cap Stocks to Buy as the S&P Makes New Highs at TheStreet
Apr-19-16 09:33AM  J&J (JNJ) Stock Gains on Q1 Earnings Beat & Improved View
Apr-17-16 10:04AM  How Much Potential Does Saxenda Hold for Novo?
Apr-16-16 03:17PM  Long views, deep pockets: Danish foundations keep pharma groups healthy AFP
Apr-15-16 11:40AM  Shire Files NDA for Chewable Version of ADHD Drug Vyvanse
11:04AM  Victoza to Fuel Growth for Novo Nordisk
10:05AM  What a Moody's upgrade means for Johnston County at
05:51AM  Moody's: Broad pipeline gains bode well for mid-term revenue and earnings of European Pharma at Moody's
Apr-14-16 11:50AM  AbbVie Reveals Positive Data on Combination HCV Therapy
Apr-13-16 01:05AM  Analyzing Novos Haemophilia and Growth Hormone Portfolio
Apr-12-16 11:10AM  Roche/AbbVie's Lymphocytic Leukemia Drug Gets FDA Nod
01:05AM  How Is Novo Nordisk Doing in the Diabetes Space?
Apr-11-16 03:30PM  Novartis Binocrit's Subcutaneous Formula Gets EC Approval
Apr-07-16 10:40AM  Novartis' Revolade Approved for Pediatric Patients in the EU
Apr-06-16 04:05PM  Why Pfizer Is Expected to Recover Growth in 1Q16
Apr-05-16 09:35AM  Grifols could receive more than $12M from county if it meets hiring projections at
Apr-04-16 04:27PM  Large Pharmaceutical Stocks Should Be On Your Buying Radar
07:05AM  What Do Analysts Expect for Pfizers Profitability?
Mar-31-16 06:47PM  Why Did Novos Share Price Fall after Fiscal 2015 Earnings?
06:46PM  What Is Novos Price-to-Earnings Valuation?
Mar-29-16 08:27AM  Emisphere Reports Fourth Quarter and Full Year 2015 Financial Results at noodls
08:00AM  Emisphere Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
03:25AM  Novo Nordisk breaks ground on USD 2bn production facility in Clayton, North Carolina at noodls
01:07AM  What Do Analysts Estimate for Novartis?
Mar-28-16 03:00PM  Novo Nordisk gives hiring update on 700 jobs pledge, breaks ground on Clayton facility at
Mar-23-16 05:45AM  America's Best Midsize Employers 2016
Mar-21-16 01:15PM  These 8 Employers Will Pay You to Volunteer at Fortune
09:21AM  Novo Nordisk A/S - Share repurchase programme at noodls
04:16AM  Chinas diabetes boom promises $23 billion pot for drug makers at MarketWatch
Mar-18-16 02:37PM  Novo Nordisk Is A Best Idea at Forbes
Mar-16-16 04:39PM  Amgen Just Won a Major Drug Patent Case Against Its Rivals at Fortune
Mar-15-16 04:33AM  Oil prices should be more comfortable: Novo Nordisk at CNBC
Mar-10-16 09:05AM  Who's Winning the Battle to Treat the Diabetic Masses? at Motley Fool
Mar-08-16 02:24PM  What Ted Cruz Gets Wrong About The FDA: Tough Regulation Can Spark Innovation at Forbes
01:12AM  Analyzing Gilead's Return on Equity (GILD, NVO) at Investopedia
Mar-07-16 04:23PM  Novo Nordisk Victoza Lowers Cardiovascular Risk Per Study
01:02PM  Novo Nordisk: The Drug Firm You've Yet to Hear Of at Investopedia
Mar-04-16 04:26PM  Novo Nordisk Pops As Diabetes Drug Cuts Heart Disease Deaths +7.89%
Mar-03-16 05:46AM  Express Scripts Says Novo Insulin Data Not Convincing Enough at Bloomberg
Mar-02-16 11:36AM  Is Citigroup Inc. (C) A Good Stock To Buy? at Insider Monkey
Mar-01-16 09:24AM  Novo Nordisk and AstraZeneca seek tonic from key drug trials
Feb-29-16 10:08AM  Demand for Hemophilia Drugs Could Grow Biogens Revenue in 2016
Feb-24-16 04:40PM  Novo Nordisk Presents Data on Tresiba and Semaglutide
Feb-23-16 02:05PM  How Much Does Novo Spend on Its Pipeline?
Feb-22-16 07:03PM  Volatility Not for You? The VEUAX May Not Be Your Cup of Tea
07:03PM  The BlackRock EuroFund: Volatility Continues into 2016
08:30AM  Healthcare Booming for Synergy, DepoMed, Novo Nordisk and United Therapeutics Accesswire
Feb-19-16 02:05AM  How Tresiba and Xultophy Will Drive Novos Performance
Feb-16-16 05:15PM  FDIVX: How Does It Hold up during Challenging Times?
Feb-15-16 07:06PM  Novo Continues to Trade at a Premium
Feb-09-16 08:25AM  Analyzing the Price Movement -- Analyst Research on Goldcorp, Questar, Dollar General and Novo Nordisk Accesswire
Feb-08-16 05:20PM  How Novos Diabetes and Obesity Care Segment Performed in 4Q15
05:08PM  Why Novo Nordisk Fell after Its 4Q15 Earnings Release
09:10AM  Morning Movers: AstraZeneca, Ralph Lauren Drop on Downgrades; Kinross Gold Jumps at
Feb-05-16 11:44AM  Novo Nordisk A/S Earnings Analysis: 2015 By the Numbers
Feb-04-16 04:15PM  Novo Nordisk A/S Taps the Growth Brakes at Motley Fool
01:40PM  Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
08:07AM  Valeant Pharmaceuticals: The Near-Term Growth Prospects
Feb-03-16 06:35AM  European Stocks Fall as Asia Declines, Earnings Disappoint at TheStreet -6.10%
06:27AM  [$$] Novo Nordisk lowers earnings targets as drug price pressure grows at Financial Times
05:13AM  Novo Nordisk CEO Sees Limited Scope for U.S. Price Increases at Bloomberg
04:53AM  [$$] Novo Nordisk Shares Plunge on Profit Growth Forecast at The Wall Street Journal
04:45AM  Drugmaker Novo surprises with long-term profit target cut
04:39AM  Novo Nordisk CEO: Optimism on Increased U.S. Access
03:18AM  More Losses for Europe Stocks as Banks Fall, Earnings Disappoint at Bloomberg
01:40AM  Novo Nordisk Quarterly Profit Misses Estimates on Victoza at Bloomberg
Jan-29-16 08:51AM  Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes at noodls
Jan-26-16 07:33AM  How Recent Events Could Affect Novo Nordisks Earnings
Jan-25-16 03:58PM  Stock Picks Worked Well for VGEAX in 2015
11:57AM  Novo Nordisk A/S - aktietilbagekøbsprogram at noodls
07:47AM  Novo Nordisk A/S - Share repurchase programme at noodls
Jan-19-16 09:14AM  Slow Global Growth: Is the Magic of Emerging Markets Over?
Jan-18-16 02:06PM  How Is Novo Nordisks Position in the Diabetes Segment?
02:04PM  What to Expect from Novo Nordisks 4Q15 Earnings
Jan-15-16 11:52AM  Can Twitter Save MannKind Corporation? at Motley Fool
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries. Novo Nordisk A/S has a collaboration agreement with the Langer Laboratory. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.